文献速递基础与转化研究新药、器械与细胞基因治疗研发

病毒进入抑制剂ARN-75039在豚鼠模型中提供抗拉沙病毒治疗性保护

The virus entry inhibitor ARN-75039 provides therapeutic protection against Lassa virus infection in guinea pigs.
PubMed 文献 · Sci Transl Med · 2026-04-15

拉沙病毒(LASV)可致拉沙热,尚无疫苗,利巴韦林疗效存疑且未正式获批。本研究在豚鼠模型中评估口服广谱沙粒病毒进入抑制剂ARN-75039,暴露后3天或7天给药均实现100%保护,动物症状轻微且病毒血症不可测。

要点

  • ARN-75039在暴露后3天或7天给药均可保护豚鼠免受致死性LASV感染。
  • 最低测试剂量3.75 mg/kg每日一次或7.5 mg/kg每日两次即达100%保护。
  • 治疗动物疾病体征轻微且病毒血症不可测,支持进一步临床开发。

核心结论

  • ARN-75039在豚鼠模型中暴露后给药可提供稳健的抗LASV保护,支持其作为拉沙热治疗候选药物。

研究设计与样本

  • 在远交Hartley豚鼠中,使用豚鼠适应LASV进行感染,评估口服生物利用的广谱沙粒病毒进入抑制剂ARN-75039。
  • ARN-75039在暴露后3天或7天开始给药,持续14天。

主要发现

  • 暴露后3天每日一次给药在两项研究中均保护豚鼠免受致死性感染。
  • 暴露后7天每日两次给药的第三项研究也实现了保护。
  • 最低测试剂量3.75 mg/kg(每日一次)或7.5 mg/kg(每日两次)均提供100%保护。
  • 治疗动物疾病体征轻微且病毒血症不可测。

关键数值与推荐

  • 最低测试剂量3.75 mg/kg每日一次或7.5 mg/kg每日两次均实现100%保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Lassa virus (LASV), a member of the Arenaviridae family, causes Lassa fever. There are no vaccines available for prevention of Lassa fever, and the primary therapeutic for treatment (ribavirin) has questionable antiviral activity and no formal approval for use. Here, we evaluated ARN-75039, an orally bioavailable broad-spectrum mammarenavirus entry inhibitor, against LASV infection in outbred Hartley guinea pigs exposed to a guinea pig-adapted LASV. ARN-75039 was administered for 14 days either 3 or 7 days postexposure (dpe) to LASV. In the first two studies, once-daily dosing at 3 dpe provided protection against lethal infection. A third study with twice-daily dosing at 7 dpe also achieved protection. Both drug regimens offered 100% protection at the lowest tested doses of 3.75 mg/kg (once-daily administration) or 7.5 mg/kg (twice-daily administration). ARN-75039-treated animals exhibited minimal disease signs and undetectable viremia. These results suggest that ARN-75039, for which a phase 1 human clinical trial has now been completed, may offer robust protection against LASV infection.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Eudy E, Woodburn D, Reeder R, et al. The virus entry inhibitor ARN-75039 provides therapeutic protection against Lassa virus infection in guinea pigs. Sci Transl Med. 2026. PMID: 41984932. doi:10.1126/scitranslmed.adx0938

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。